Compare KKR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KKR | SNY |
|---|---|---|
| Founded | 1976 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.0B | 119.4B |
| IPO Year | 2010 | N/A |
| Metric | KKR | SNY |
|---|---|---|
| Price | $136.52 | $48.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $155.07 | $61.50 |
| AVG Volume (30 Days) | ★ 4.4M | 2.6M |
| Earning Date | 11-07-2025 | 01-29-2026 |
| Dividend Yield | 0.54% | ★ 3.28% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 2.37 | ★ 8.67 |
| Revenue | $22,245,686,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $31.86 | $6.47 |
| P/E Ratio | $57.72 | ★ $5.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.15 | $44.62 |
| 52 Week High | $170.40 | $60.12 |
| Indicator | KKR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 65.00 | 43.35 |
| Support Level | $119.09 | $47.80 |
| Resistance Level | $144.84 | $49.24 |
| Average True Range (ATR) | 3.99 | 0.64 |
| MACD | 2.19 | -0.16 |
| Stochastic Oscillator | 71.00 | 29.77 |
KKR is one of the world's largest alternative asset managers, with $723.2 billion in total managed assets, including $585.0 billion in fee-earning AUM, at the end of September 2025. The company has two core segments: asset management (which includes private markets—private equity, credit, infrastructure, energy, and real estate—and public markets—primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.